Circle Biosciences (Immatics) and Cellular Origins agreed to use Cellular Origins’ automated mobile robotic platform, Constellation, across parts of Immatics’ cell therapy manufacturing workflows. The collaboration aims to improve efficiency and scalability as Immatics advances precision targeting approaches involving PRAME across multiple cancers. The companies said the partnership could help expand access to approved therapies by reducing reliance on manual manufacturing processes that constrain patient capacity. Immatics also pointed to its clinically validated PRAME targeting data and said scalable manufacturing capabilities will be important for future approvals in solid tumors. For the broader cell therapy ecosystem, the deal highlights a shift toward automation-first operational strategies as developers try to compress time, reduce variability, and scale supply chains without compromising quality attributes.